Insider selling is negligible and does not indicate a coordinated bearish view. Director grants are standard compensation. Monitor upcoming clinical catalysts (pipeline updates) for fundamental direction; insider activity provides no actionable signal.
LYEL drugs
LYEL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 16 $12.44entry
- T+1 · 5mo ago +0.64%α +1.89% · $12.52
- T+5 · 5mo ago +1.53%α +3.76% · $12.63
- T+20 · 4mo ago +7.72%α +7.52% · $13.40
- T+60 · 2mo ago −1.93%α −2.93% · $12.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lyell Immunopharma insiders executed negligible open-market sales totaling $8K (0.003% of market cap) in early May 2026, alongside routine director stock grants. A separate June 2026 cluster shows a CMO sale of $25K and additional director grants, but combined insider activity remains immaterial relative to the $315M market cap. No bearish signal from insider trading.
Key Financial Metrics
Key Facts
- Three insiders (COO, CSO, VP Controller) sold a total of 436 shares for $8K on May 11, 2026.
- Seven directors received non-cash grants of 9,250 shares each on June 10, 2026 (total $0).
- CMO Shook David sold 1,977 shares for $25K on June 10, 2026.
- Total open-market sales across both clusters: $33K, representing ~0.01% of market cap.
- All sales are routine in size and likely tax-related or diversification trades.
Financial Impact
Total open-market insider sales of approximately $33K, representing 0.01% of Lyell's $315M market cap.
Risk Factors
- No material insider risk from these trades.
- Primary risk remains Lyell's pre-revenue status and cash burn rate.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-LYEL-1781562965891 |
Track record
21 reports on LYEL
5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
- Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
- Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
- Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
- Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers